Oxurion

Oxurion EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Oxurion (OXUR.BR) as of Oct 15, 2026 is -5.49. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.14 — a change of 381.22% (lower).

EV/FCF

-5.49

YoY

381.22%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Oxurion is 2024 -5.49 . EV/FCF (Enterprise Value to Free Cash Flow) of Oxurion was 2023 -1.14 . It decreases by 381.22% lower compared to the previous year.

The Oxurion EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-4.04 EUR
Jan 1, 2018
2.70 EUR
Jan 1, 2019
1.61 EUR
Jan 1, 2020
0.85 EUR
Jan 1, 2021
-0.10 EUR
Jan 1, 2022
-0.25 EUR
Jan 1, 2023
-1.14 EUR
Jan 1, 2024
-5.49 EUR
The Oxurion EV/FCF history
YEAREV/FCFYoY
-5.49+381.22%
-1.14+351.60%
-0.25+162.54%
-0.10-111.28%
0.85-46.96%
1.61-40.47%
2.70-166.91%
-4.04-211.09%
3.64+1.44%
3.59+33.54%
2.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oxurion Stock analysis

What does Oxurion do? Oxurion NV is a biotechnology company based in Heverlee, Belgium, operating within the healthcare sector. The company has 77 employees and went public on July 7, 2006. Oxurion focuses on developing and commercializing treatments for vitreoretinal diseases. Its lead product, JETREA (ocriplasmin), received U.S. Food and Drug Administration approval for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. The company collaborates with Alcon, a division of Novartis, for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including cases associated with macular holes of 400 microns or smaller, with launches in the United Kingdom and Germany. Oxurion is also researching anti-PIGF (Placental Growth Factor), known as TB-403, for potential use in ophthalmic and oncology treatments. The company maintains operations in Belgium, the United States, and Ireland, with its headquarters in Heverlee, Vlaams-Brabant. Oxurion's website is www.oxurion.com. Oxurion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oxurion stock

EV/FCF (Enterprise Value to Free Cash Flow) of Oxurion is -5.49 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Oxurion changed from -1.14 to -5.49, representing a 381.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Oxurion since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Oxurion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Oxurion

All Key Metrics — Oxurion